Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.

Pratt G, Bowcock S, Lai M, Bell S, Bird J, D'Sa S, Cavenagh J, Cook G, Morgan G, Owen R, Snowden JA, Yong K, Davies F; United Kingdom Myeloma Forum..

Int J Lab Hematol. 2014 Feb;36(1):20-8. doi: 10.1111/ijlh.12097.

PMID:
23615178
2.

Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.

Palumbo A, Offidani M, Patriarca F, Petrucci MT, Cavo M.

Leuk Lymphoma. 2015 Mar;56(3):559-67. doi: 10.3109/10428194.2014.915545. Review.

PMID:
24884319
3.

Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.

Musto P, Fraticelli VL, Mansueto G, Madonna E, Nozza A, Andriani A, Mussetti A, Ballanti S, Bongarzoni V, Baraldi A, Patriarca F, Vincelli D, Falcone A, Derudas D, Califano C, Zambello R, Mele G, Fragasso A, Baldini L, Storti S.

Leuk Lymphoma. 2015 May;56(5):1510-3. doi: 10.3109/10428194.2014.982644. No abstract available.

PMID:
25651428
4.

An old drug with a new future: bendamustine in multiple myeloma.

Gentile M, Recchia AG, Mazzone C, Vigna E, Martino M, Morabito L, Lucia E, Bossio S, De Stefano L, Granata T, Palummo A, Morabito F.

Expert Opin Pharmacother. 2013 Nov;14(16):2263-80. doi: 10.1517/14656566.2013.837885. Review.

PMID:
24053161
5.

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.

Stöhr E, Schmeel FC, Schmeel LC, Hänel M, Schmidt-Wolf IG; German Refractory Myeloma Study Group..

J Cancer Res Clin Oncol. 2015 Dec;141(12):2205-12. doi: 10.1007/s00432-015-2014-2.

PMID:
26156122
6.

United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.

Rabin N, Lai M, Pratt G, Morgan G, Snowden J, Bird J, Cook G, Bowcock S, Owen R, Yong K, Wechalaker A, Low E, Davies F; United Kingdom Myeloma Forum..

Int J Lab Hematol. 2014 Dec;36(6):665-75. doi: 10.1111/ijlh.12205.

PMID:
24673823
7.

The role of bendamustine in the management of plasma cell myeloma.

Gertz MA.

Leuk Lymphoma. 2015 May;56(5):1195-6. doi: 10.3109/10428194.2014.977888. No abstract available.

PMID:
25347428
8.

Bendamustine in multiple myeloma.

Gentile M, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F.

Eur J Haematol. 2015 Nov;95(5):377-88. doi: 10.1111/ejh.12609. Review.

PMID:
26085055
9.

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633.

PMID:
26179864
10.

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.

Damaj G, Malard F, Hulin C, Caillot D, Garidi R, Royer B, Marit G, Stoppa AM, Banos A, Morineau N, Moreau P, Fitoussi O, Tiab M, Moreau P.

Leuk Lymphoma. 2012 Apr;53(4):632-4. doi: 10.3109/10428194.2011.622422.

PMID:
21916831
11.

Bendamustine in the treatment of multiple myeloma: results and future perspectives.

Pönisch W, Niederwieser D.

Semin Oncol. 2002 Aug;29(4 Suppl 13):23-6.

PMID:
12170429
12.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U, Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U, Niederwieser D; East German Study Group of Haematology and Oncology (OSHO)..

Br J Haematol. 2008 Oct;143(2):191-200. doi: 10.1111/j.1365-2141.2008.07076.x.

PMID:
18752593
13.

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL.

Leuk Lymphoma. 2016;57(4):766-82. doi: 10.3109/10428194.2015.1099647. Review.

14.

Bendamustine: role and evidence in lymphoma therapy, an overview.

Derenzini E, Zinzani PL, Cheson BD.

Leuk Lymphoma. 2014 Jul;55(7):1471-8. doi: 10.3109/10428194.2013.842986. Review.

PMID:
24180334
15.

Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, Akutsu M, Mori S, Nakamura Y, Ueda T, Kano Y, Furukawa Y.

PLoS One. 2014 Mar 13;9(3):e90675. doi: 10.1371/journal.pone.0090675.

16.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.

Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al-Ali HK, Jäkel N, Niederwieser D.

Br J Haematol. 2013 Jul;162(2):202-9. doi: 10.1111/bjh.12361.

PMID:
23692564
17.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D.

Br J Haematol. 2013 Feb;160(3):321-30. doi: 10.1111/bjh.12129.

PMID:
23150919
18.

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, Ali HA, Niederwieser D.

J Cancer Res Clin Oncol. 2013 Mar;139(3):499-508. doi: 10.1007/s00432-012-1339-3.

PMID:
23184429
19.

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.

Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K.

Ann Hematol. 2015 Apr;94(4):643-9. doi: 10.1007/s00277-014-2238-2.

PMID:
25345871
20.

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.

Schey S, Brown SR, Tillotson AL, Yong K, Williams C, Davies F, Morgan G, Cavenagh J, Cook G, Cook M, Orti G, Morris C, Sherratt D, Flanagan L, Gregory W, Cavet J; Myeloma UK Early Phase Clinical Trial Network..

Br J Haematol. 2015 Aug;170(3):336-48. doi: 10.1111/bjh.13435.

PMID:
25891006
Items per page

Supplemental Content

Support Center